Ads
related to: statins that don't affect memory development problems and anxiety- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Co-Pay Program
Resources
to Support Your Patients
- Request Samples
Get patients started
with a 14-day sample
- Trial Results
See Clinical Data
and Trial
- Patient Identification
View a Patient Profile
to Learn More
- MOA
Mechanism of Action -
Watch A Video To Learn More
- Dosing & Administration
wiserlifestyles.com has been visited by 100K+ users in the past month
nexlizet.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Serious side effects may include rhabdomyolysis, liver problems, and diabetes. [6] Use during pregnancy may harm the baby. [6] Like all statins, rosuvastatin works by inhibiting HMG-CoA reductase, an enzyme found in the liver that plays a role in producing cholesterol. [6]
Statin-induced rhabdomyolysis is rare, occurring in less than 0.1% of people who take statins. [66] [67] [68] Statin induced rhabdomyolysis, as with other statin associated muscle symptoms, occurs most commonly in the first year of treatment but can occur at any time during treatment. [66]
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug.In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [1]
Media reporting on statins is often negative, and patient leaflets inform patients that rare but potentially serious muscle problems can occur during statin treatment. These create expectations of harm. Nocebo symptoms are real and bothersome and are a major barrier to treatment.
When depression is severe, it may also lead to a condition called pseudodementia, characterized by dementia-like symptoms including memory loss, difficulty concentrating and poor decision-making ...
The statins differ with respect to their ring structure and substituents. These differences in structure affect the pharmacological properties of the statins, such as: [6] Affinity for the active site of the HMGR; Rates of entry into hepatic and non-hepatic tissues; Availability in the systemic circulation for uptake into non-hepatic tissues